Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | GSR | P00390 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3371717 | 0.85 | MAPT (0.34) | MAPTGABRR1GSR | |
| SCHEMBL8815879 | 0.83 | TET2 (0.30) | — | |
| Hydrochloric Acid SCHEMBL11748274 | 0.83 | MAPT (0.33) | MAPTGSR | |
| SCHEMBL3367886 | 0.83 | MAPT (0.38) | MAPTGSR | |
| SCHEMBL25269390 | 0.81 | MAPT (0.41) | MAPTGSR | |
| SCHEMBL3365115 | 0.81 | MAPT (0.41) | MAPTGSR | |
| SCHEMBL3367805 | 0.81 | MAPT (0.41) | MAPTGSR | |
| SCHEMBL366788 | 0.81 | — | — | |
| SCHEMBL3132073 | 0.81 | — | — | |
| SCHEMBL3371519 | 0.81 | MAPT (0.41) | MAPTGSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116656203-B | Coating composition with mildew-proof and antibacterial properties and preparation method thereof | 江西永通科技股份有限公司 | 2023-10-27 | — | — | CN | claimed |
| CN-116656203-A | Coating composition with mildew-proof and antibacterial properties and preparation method thereof | 江西永通科技股份有限公司 | 2023-08-29 | — | — | CN | claimed |
| US-20250361280-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250170216-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20240226225-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240209053-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240066131-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240018189-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| CN-116656203-B | Coating composition with mildew-proof and antibacterial properties and preparation method thereof | 江西永通科技股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-20230295259-A1 | Conjugated Hepcidin Mimetics | PROTAGONIST THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| CN-116656203-A | Coating composition with mildew-proof and antibacterial properties and preparation method thereof | 江西永通科技股份有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-102046179-A | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS INC | 2011-05-04 | — | — | CN | disclosed |
| CN-101743231-A | Isoxazoline compounds and their use to control pests | SUMITOMO CHEMICAL CO | 2010-06-16 | — | — | CN | disclosed |
| CN-101341127-A | 4,5-dihydro- (1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators | SOLVAY PHARM BV (NL) | 2009-01-07 | — | — | CN | disclosed |
| EP-1261611-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-12-04 | — | — | EP | disclosed |
| EP-1252178-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001064678-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001040262-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-06-07 | — | — | WO | disclosed |
| EP-0998488-A1 | POLYOL-AMINO ACID COMPOUNDS HAVING ANTI-HELICOBACTER PYLORI ACTIVITY | Takeda Chemical Industries, Ltd. (JP) | 2000-05-10 | — | — | EP | disclosed |
| WO-1999002549-A1 | POLYOL-AMINO ACID COMPOUNDS HAVING ANTI-HELICOBACTER PYLORI ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018189-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | MAPT 4733/4885GABRR1 3718/4885GSR 2345/4885 |
| US-20230295259-A1 | Conjugated Hepcidin Mimetics | HAMP, VIP, HDGF | MAPT 4733/4885GABRR1 3718/4885GSR 2345/4885 |
| US-20250361280-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | MAPT 4660/4885GABRR1 3827/4885GSR 2619/4885 |
| US-20240066131-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | MAPT 4733/4885GABRR1 3718/4885GSR 2345/4885 |
| US-20240226225-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, SLC40A1, FTH1 | MAPT 3675/4885GABRR1 4009/4885GSR 1720/4885 |
| US-20240209053-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, SLC40A1, FTH1 | MAPT 3901/4885GABRR1 3959/4885GSR 1510/4885 |
| US-20250170216-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | MAPT 4776/4885GABRR1 3429/4885GSR 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.